Sanofi to Acquire Diabetes Therapy Maker Provention Bio for $2.9B
What You Should Know:– Sanofi has agreed to acquire Provention Bio, Inc., a U.S.-based, publicly traded biopharmaceutical company focused on intercepting and preventing immune-mediated diseases including type 1 diabetes (T1D), for $25.00 per share in cash, representing an equity…
Continue Reading